BCAX
Bicara Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.12
−6.27%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.84
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.82
- EPS estimate
- -$0.82
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +0.8%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $29
- PT range
- $20 – $39
- Analysts
- 7
4 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.82 | -$0.82 | Miss -0.03% | — |
| May 11, 2026 | -$0.64 | -$0.93 | Miss -45.31% | — |
| Mar 30, 2026 | -$0.66 | -$0.39 | Beat 41.33% | — |
| Aug 12, 2025 | -$0.54 | -$0.50 | Beat 7.41% | — |
| Mar 27, 2025 | -$0.31 | -$0.39 | Miss -25.81% | — |
| Sep 13, 2024 | — | -$0.27 | — | — |
| Jun 30, 2024 | — | -$0.27 | — | — |
| Dec 31, 2023 | — | -$0.23 | — | — |
| Sep 30, 2023 | — | -$0.42 | — | — |
| Jun 30, 2023 | — | -$0.15 | — | — |
| Mar 31, 2023 | — | -$0.15 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026